首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study
Authors:Hasan UBUK  Mehmet ZB&#x;L
Institution:1. Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, İstanbul Arel University, İstanbul, Turkey ; 2. Institute of Biotechnology, Gebze Technical University, Kocaeli, Turkey
Abstract:The new type of coronavirus, SARS-CoV-2 has affected more than 22.6 million people worldwide. Since the first day the virus was spotted in Wuhan, China, numerous drug design studies have been conducted all over the globe. Most of these studies target the receptor-binding domain of spike protein of SARS-CoV-2, which is known to bind to the human ACE2 receptor and SARS-CoV-2 main protease, vital for the virus’ replication. However, there might be a third target, human furin protease, which cleaves the virus’ S1-S2 domains playing an active role in its entry into the host cell. In this study, we docked five clinically used drug molecules, favipiravir, hydroxychloroquine, remdesivir, lopinavir, and ritonavir onto three target proteins, the receptor-binding domain of SARS-CoV-2 spike protein, SARS-CoV-2 main protease, and human furin protease. Results of molecular docking simulations revealed that human furin protease might be targeted by COVID-19. Remdesivir, a nucleic acid derivative, strongly bound to the active site of this protease, suggesting that this molecule can be used as a template for designing novel furin protease inhibitors to fight against the disease. Protein-drug interactions revealed in this study at the molecular level, can pave the way for better drug design for each specific target.
Keywords:SARS-CoV-2  COVID-19  furin protease  remdesivir  molecular docking
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号